Skin-Disease Focused Biotech Castle Creek Files $100M IPO

  • Ahead of Phase 3 data readout in the second half of next year, Castle Creek Biosciences Inc CCBS seeks to make NASDAQ debut under the symbol CCBS.
  • The Company's advanced product candidate, dabocemagene autoficel or D-Fi, is under development for recessive dystrophic epidermolysis bullosa, a rare disease caused by a lack of collagen in the skin resulting in uncontrollable blistering. 
  • It's a program that comes from the small acquisition of the biotech Fibrocell back in September 2019.
  • The biotech plans to launch a second Phase 3 study in the second half of 2021 in the dominant version of dystrophic epidermolysis bullosa. 
  • Though Castle Creek did not divulge exact figures in its SEC paperwork, it's expected that a significant portion of these funds will go toward the two studies and "pre-commercial" activities for D-Fi.
  • IPO prospectus filing here
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingOfferingsIPOsGeneralBriefsSkin Disorder
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!